By: Caitlin A. Koppenhaver, Attorney
FDA’s April 1 approval of Foundayo (orforglipron) is getting attention because it adds an oral GLP-1 option to the market. But the more interesting development, at least from a regulatory-process standpoint, is what FDA is doing with the Commissioner’s National Priority Voucher (CNPV) pilot program. FDA said this was the first new molecular entity (NME) approved under the program, the fifth approval overall under CNPV, and that the decision came 50 days after filing and 294 days before the application’s original PDUFA date of January 20, 2027. FDA also called it the fastest approval of a new molecular entity since 2002.
So, why was this faster than other drug applications? FDA’s answer is that this was not handled through an ordinary review track. The agency says the CNPV pilot, announced in June 2025, is being explored as a pathway to dramatically reduce review times for certain drug and biologic applications that align with one of FDA’s stated national health priorities. FDA describes the target timeline as 1-2 months target, compared to 6+ months for other FDA priority review programs.
FDA has also been unusually clear about what kinds of products it wants in this program. On the program overview page, the agency lists five priority areas:
- Public health crisis response - Products addressing urgent/emerging threats or significant population impact.
- Innovative breakthrough therapies - Transformative treatments with novel mechanisms that fundamentally change disease management.
- Large unmet medical needs - Therapies for conditions where existing treatments inadequately address patient outcomes.
- Onshoring and supply chain resilience - Onshoring drug development/manufacturing to strengthen U.S. domestic capacity, reduce foreign dependencies, and improve national security.
Affordability - Approaches that improve overall value through reduced costs to the healthcare system or that enhance access to important products.
In its November 2025 announcement awarding the second batch of vouchers, FDA further said these vouchers are granted to a select group of products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need.
That means the speed here was not random. The application had already been selected into a pilot program built for compressed review. FDA announced on November 6, 2025 that orforglipron was among the second batch of CNPV recipients. By the time Foundayo was approved on April 1, 2026, FDA said it had awarded 18 vouchers and issued six decisions under the program.
FDA also laid out the mechanics of why CNPV moves faster. The agency points to enhanced communications, rolling review, enhanced presubmission requests, and a multidisciplinary “tumor board-style” discussion between the review team and senior agency leadership. In its Foundayo announcement, FDA said it was able to move quickly by cutting idle time and maintaining constant communications with the company throughout the review process.
Just as important, FDA is also trying to make clear what the program is not. The agency says CNPV maintains the same safety and effectiveness approval standards, the same scientific rigor, and the same regulatory compliance requirements. FDA also states that products in the program remain subject to the same statutory and regulatory requirements for approval as applications outside the program, and that the final approval decision still remains with the relevant FDA center using its normal processes.
So the larger point here is not just that FDA approved another GLP-1 product. It is that FDA is openly testing a different review model: one that builds in more work before submission, shortens dead time between review steps, keeps sponsors in close contact with the agency, and uses a more concentrated internal review structure once the application is in. Foundayo appears to be the clearest example so far of that model in action.
And, candidly, that is part of what makes this hard not to read with a little frustration for the peptide and broader wellness industry. It is certainly interesting to see FDA move this quickly on an oral GLP-1 approval. But it also leaves a fair question hanging in the background: where is the same urgency, follow-up, or even acknowledgement on the ongoing Category 2 discussion?